David M.  Obstler net worth and biography

David Obstler Biography and Net Worth

CFO of Precigen
David Obstler is the chief financial officer for Datadog, a software company. 

Obstler joined Datadog in 2018 after spending over four years as TravelClick’s CFO. During his time with TravelClick, Obstler served as a member of the company’s leadership team and led its global financial operations from 2014 to 2018. 

Obstler’s career spans three decades of financial expertise, beginning with his time in investment banking at firms such as Goldman Sachs, Lehman Brothers and JPMorgan. From 2000 to 2004, he was the CFO of Pinnacor, moving on to become CFO of Risk Metrics Group from 2005 to 2010. The company is now part of MSCI. 

Prior to his time with TravelClick, Obstler spent just over two years as MSCI’s CFO. From 2012 to 2014, he served as CFO of OpenLink Financial. 

Obstler received his B.A. from Yale University and his M.B.A. from Harvard Business School.

What is David M. Obstler's net worth?

The estimated net worth of David M. Obstler is at least $258,614.87 as of October 11th, 2024. Mr. Obstler owns 314,158 shares of Precigen stock worth more than $258,615 as of November 5th. This net worth approximation does not reflect any other investments that Mr. Obstler may own. Learn More about David M. Obstler's net worth.

How do I contact David M. Obstler?

The corporate mailing address for Mr. Obstler and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on David M. Obstler's contact information.

Has David M. Obstler been buying or selling shares of Precigen?

David M. Obstler has not been actively trading shares of Precigen in the last ninety days. Learn More on David M. Obstler's trading history.

Who are Precigen's active insiders?

Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.

Are insiders buying or selling shares of Precigen?

In the last year, Precigen insiders bought shares 2 times. They purchased a total of 155,509 shares worth more than $186,326.81. The most recent insider tranaction occured on August, 9th when SVP Jeffrey Thomas Perez bought 58,823 shares worth more than $49,999.55. Insiders at Precigen own 44.9% of the company. Learn More about insider trades at Precigen.

Information on this page was last updated on 8/9/2024.

David M. Obstler Insider Trading History at Precigen

See Full Table

David M. Obstler Buying and Selling Activity at Precigen

This chart shows David M Obstler's buying and selling at Precigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Precigen Company Overview

Precigen logo
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More

Today's Range

Now: $0.82
Low: $0.80
High: $0.84

50 Day Range

MA: $0.95
Low: $0.79
High: $1.15

2 Week Range

Now: $0.82
Low: $0.79
High: $1.93

Volume

707,573 shs

Average Volume

950,035 shs

Market Capitalization

$208.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68